Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Dyslipidemia

Free Subscription Articles published in Curr Opin Lipidol Retrieve available abstracts of 65 articles: HTML format

Single Articles

August 2024
1. FOSTER C, Gagnon CA, Ashraf AP
   Altered lipid metabolism and the development of metabolic-associated fatty liver disease.
   Curr Opin Lipidol. 2024;35:200-207.
   PubMed     Abstract available
   
   
   June 2024
2. BASHIR B, Ferdousi M, Durrington PN, Soran H, et al
   Pancreatic and cardiometabolic complications of severe hypertriglyceridaemia.
   Curr Opin Lipidol. 2024 Jun 7. doi: 10.1097/MOL.0000000000000939.
   PubMed     Abstract available
   
   
   
3. MULDER JWCM, Kusters DM, Roeters van Lennep JE, Hutten BA, et al
   Lipid metabolism during pregnancy: consequences for mother and child.
   Curr Opin Lipidol. 2024;35:133-140.
   PubMed     Abstract available
   
   
   April 2024
4. BRUNHAM LR
   Familial hypercholesterolemia-Plus: is the metabolic syndrome changing the clinical picture of familial hypercholesterolemia?
   Curr Opin Lipidol. 2024 Apr 22. doi: 10.1097/MOL.0000000000000938.
   PubMed     Abstract available
   
   
   
5. CIVEIRA F, Martin C, Cenarro A
   APOE and familial hypercholesterolemia.
   Curr Opin Lipidol. 2024 Apr 17. doi: 10.1097/MOL.0000000000000937.
   PubMed     Abstract available
   
   
   
6. RASMUSSEN KL, Frikke-Schmidt R
   The current state of apolipoprotein E in dyslipidemia.
   Curr Opin Lipidol. 2024;35:78-84.
   PubMed     Abstract available
   
   
   
7. WEN Y, Chen YQ, Konrad RJ
   Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism.
   Curr Opin Lipidol. 2024;35:58-65.
   PubMed     Abstract available
   
   
   February 2024
8. CHAN DC, Watts GF
   ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
   Curr Opin Lipidol. 2024 Feb 20. doi: 10.1097/MOL.0000000000000920.
   PubMed     Abstract available
   
   
   
9. VAN DEN BOSCH SE, Hutten BA, Corpeleijn WE, Kusters DM, et al
   Familial hypercholesterolemia in children and the importance of early treatment.
   Curr Opin Lipidol. 2024 Feb 15. doi: 10.1097/MOL.0000000000000926.
   PubMed     Abstract available
   
   
   
10. PAPONJA K, Pecin I, Reiner Z, Banach M, et al
    Bempedoic acid: new evidence and recommendations on use.
    Curr Opin Lipidol. 2024;35:41-50.
    PubMed     Abstract available
    
    
    
11. ZHANG Y, de Ferranti SD, Moran AE
    Genetic testing for familial hypercholesterolemia.
    Curr Opin Lipidol. 2024 Feb 1. doi: 10.1097/MOL.0000000000000925.
    PubMed     Abstract available
    
    
    December 2023
12. PERERA SD, Hegele RA
    Genetic variation in apolipoprotein A-V in hypertriglyceridemia.
    Curr Opin Lipidol. 2023 Dec 21. doi: 10.1097/MOL.0000000000000916.
    PubMed     Abstract available
    
    
    
13. ROMERO-JIMENEZ MJ, Mansilla-Rodriguez ME, Gutierrez-Cortizo EN
    Predictors of cardiovascular risk in familial hypercholesterolemia.
    Curr Opin Lipidol. 2023;34:272-277.
    PubMed     Abstract available
    
    
    
14. GILLARD BK, Rosales C, Gotto AM Jr, Pownall HJ, et al
    The pathophysiology of excess plasma-free cholesterol.
    Curr Opin Lipidol. 2023;34:278-286.
    PubMed     Abstract available
    
    
    
15. KARALIS DG
    Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:252-258.
    PubMed     Abstract available
    
    
    November 2023
16. ROY G, Drouin-Chartier JP
    Cardiovascular disease prevention in heterozygous familial hypercholesterolemia: how important is a healthy diet in the era of long-lasting cholesterol-lowering drug therapies?
    Curr Opin Lipidol. 2023 Nov 2. doi: 10.1097/MOL.0000000000000908.
    PubMed     Abstract available
    
    
    October 2023
17. CHATTOPADHYAY A, Reddy ST, Fogelman AM
    The multiple roles of lysophosphatidic acid in vascular disease and atherosclerosis.
    Curr Opin Lipidol. 2023;34:196-200.
    PubMed     Abstract available
    
    
    August 2023
18. CHOUDHARI P, Patni N
    Updates in the management of pediatric dyslipidemia.
    Curr Opin Lipidol. 2023;34:156-161.
    PubMed     Abstract available
    
    
    June 2023
19. GANDA OP
    Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:105-113.
    PubMed     Abstract available
    
    
    
20. WADSTROM BN, Pedersen KM, Wulff AB, Nordestgaard BG, et al
    Inflammation compared to low-density lipoprotein cholesterol: two different causes of atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:96-104.
    PubMed     Abstract available
    
    
    April 2023
21. CLARKE SL
    Does low-density lipoprotein fully explain atherosclerotic risk in familial hypercholesterolemia?
    Curr Opin Lipidol. 2023;34:52-58.
    PubMed     Abstract available
    
    
    
22. HEGELE RA
    DNA testing in dyslipidemia: attitudes and complexities.
    Curr Opin Lipidol. 2023;34:33-34.
    PubMed    
    
    
    March 2023
23. VUORIO A, Raal F, Kovanen PT
    Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19.
    Curr Opin Lipidol. 2023 Mar 10. doi: 10.1097/MOL.0000000000000876.
    PubMed     Abstract available
    
    
    February 2023
24. HANG SMT, Hegele RA, Berberich AJ
    Genetic determinants of pancreatitis: relevance in severe hypertriglyceridemia.
    Curr Opin Lipidol. 2023 Feb 2. doi: 10.1097/MOL.0000000000000866.
    PubMed     Abstract available
    
    
    January 2023
25. REIJMAN MD, Defesche JC, Wiegman A
    Genotype-phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia.
    Curr Opin Lipidol. 2023 Jan 18. doi: 10.1097/MOL.0000000000000863.
    PubMed     Abstract available
    
    
    December 2022
26. DRON JS
    The clinical utility of polygenic risk scores for combined hyperlipidemia.
    Curr Opin Lipidol. 2022 Dec 28. doi: 10.1097/MOL.0000000000000865.
    PubMed     Abstract available
    
    
    
27. WEI T, Cho L
    Recent lipoprotein(a) trials.
    Curr Opin Lipidol. 2022;33:301-308.
    PubMed     Abstract available
    
    
    
28. MENDOZA MF, Lavie CJ
    Clinical associations between exercise and lipoproteins.
    Curr Opin Lipidol. 2022;33:364-373.
    PubMed     Abstract available
    
    
    
29. TRAMONTANO D, Bini S, D'Erasmo L, Arca M, et al
    Recent Apolipoprotein CIII trials.
    Curr Opin Lipidol. 2022;33:309-318.
    PubMed     Abstract available
    
    
    October 2022
30. TROMP TR, Cuchel M
    New algorithms for treating homozygous familial hypercholesterolemia.
    Curr Opin Lipidol. 2022 Oct 5. pii: 00041433-990000000-00014.
    PubMed     Abstract available
    
    
    
31. SCIPIONE CA, Cybulsky MI
    Early atherogenesis: new insights from new approaches.
    Curr Opin Lipidol. 2022;33:271-276.
    PubMed     Abstract available
    
    
    August 2022
32. MARTINS J, Rossouw HM, Pillay TS
    How should low-density lipoprotein cholesterol be calculated in 2022?
    Curr Opin Lipidol. 2022;33:237-256.
    PubMed     Abstract available
    
    
    July 2022
33. LEREN TP, Bogsrud MP
    Cascade screening for familial hypercholesterolemia should be organized at a national level.
    Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00004.
    PubMed     Abstract available
    
    
    
34. DURRINGTON PN, Bashir B, Bhatnagar D, Soran H, et al
    Lipoprotein (a) in familial hypercholesterolaemia.
    Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00005.
    PubMed     Abstract available
    
    
    
35. PAQUETTE M, Bernard S, Baass A
    Diagnosis of remnant hyperlipidaemia.
    Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00002.
    PubMed     Abstract available
    
    
    June 2022
36. THEROND P, Chapman MJ
    Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment.
    Curr Opin Lipidol. 2022;33:199-207.
    PubMed     Abstract available
    
    
    April 2022
37. WHITTAKER MN, Musunuru K
    Therapeutic application of genome editing in dyslipidemia.
    Curr Opin Lipidol. 2022;33:133-138.
    PubMed     Abstract available
    
    
    February 2022
38. SACKS FM, Andraski AB
    Dietary fat and carbohydrate affect the metabolism of protein-based high-density lipoprotein subspecies.
    Curr Opin Lipidol. 2022;33:1-15.
    PubMed     Abstract available
    
    
    December 2021
39. ANTONIAZI L, Arroyo-Olivares R, Mata P, Santos RD, et al
    Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia.
    Curr Opin Lipidol. 2021 Dec 13. pii: 00041433-900000000-99240.
    PubMed     Abstract available
    
    
    
40. MEDEIROS AM, Bourbon M
    Polygenic contribution for familial hypercholesterolemia (FH).
    Curr Opin Lipidol. 2021;32:392-395.
    PubMed     Abstract available
    
    
    
41. CHAN DC, Ying Q, Watts GF
    Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies.
    Curr Opin Lipidol. 2021;32:378-385.
    PubMed     Abstract available
    
    
    
42. MATA P, Alonso R, Perez de Isla L, Badimon L, et al
    Dyslipidemia and aortic valve disease.
    Curr Opin Lipidol. 2021;32:349-354.
    PubMed     Abstract available
    
    
    
43. KERSTEN S
    ANGPTL3 as therapeutic target.
    Curr Opin Lipidol. 2021;32:335-341.
    PubMed     Abstract available
    
    
    October 2021
44. GILL PK, Hegele RA
    Familial combined hyperlipidemia is a polygenic trait.
    Curr Opin Lipidol. 2021 Oct 22. pii: 00041433-900000000-99252.
    PubMed     Abstract available
    
    
    
45. MCINTOSH CS, Watts GF, Wilton SD, Aung-Htut MT, et al
    Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations.
    Curr Opin Lipidol. 2021 Oct 15. pii: 00041433-900000000-99253.
    PubMed     Abstract available
    
    
    
46. GRAHAM DF, Raal FJ
    Management of familial hypercholesterolemia in pregnancy.
    Curr Opin Lipidol. 2021 Oct 6. pii: 00041433-900000000-99256.
    PubMed     Abstract available
    
    
    September 2021
47. THOMPSON GR
    Use of apheresis in the age of new therapies for familial hypercholesterolaemia.
    Curr Opin Lipidol. 2021 Sep 22. pii: 00041433-900000000-99259.
    PubMed     Abstract available
    
    
    August 2021
48. IQBAL Z, Bashir B, Ferdousi M, Kalteniece A, et al
    Lipids and peripheral neuropathy.
    Curr Opin Lipidol. 2021;32:249-257.
    PubMed     Abstract available
    
    
    
49. DRON JS, Hegele RA
    Editorial: Discussing polygenic risk with lipid clinic patients.
    Curr Opin Lipidol. 2021;32:273-275.
    PubMed    
    
    
    June 2021
50. BERBERICH AJ, Hegele RA
    Lipid effects of glucagon-like peptide 1 receptor analogs.
    Curr Opin Lipidol. 2021;32:191-199.
    PubMed     Abstract available
    
    
    April 2021
51. MOHAMED F, Botha TC, Raal FJ
    Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.
    Curr Opin Lipidol. 2021 Apr 20. pii: 00041433-900000000-99277.
    PubMed     Abstract available
    
    
    
52. PULIPATI VP, Davidson MH
    The clinical black, white, and gray lessons.
    Curr Opin Lipidol. 2021;32:151-156.
    PubMed     Abstract available
    
    
    
53. WAND H, Knowles JW, Clarke SL
    The need for polygenic score reporting standards in evidence-based practice: lipid genetics use case.
    Curr Opin Lipidol. 2021;32:89-95.
    PubMed     Abstract available
    
    
    
54. BROWN EE
    The genetic counselor's role in management of patients with dyslipidemia.
    Curr Opin Lipidol. 2021;32:83-88.
    PubMed     Abstract available
    
    
    
55. TRINDER M, Brunham LR
    Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance.
    Curr Opin Lipidol. 2021;32:103-111.
    PubMed     Abstract available
    
    
    
56. FONG V, Patel SB
    Recent advances in ABCG5 and ABCG8 variants.
    Curr Opin Lipidol. 2021;32:117-122.
    PubMed     Abstract available
    
    
    February 2021
57. CHORA JR, Bourbon M
    Pharmacogenomics of statins and familial hypercholesterolemia.
    Curr Opin Lipidol. 2021 Feb 10. pii: 00041433-900000000-99283.
    PubMed     Abstract available
    
    
    October 2020
58. YEANG C, Willeit P, Tsimikas S
    The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia.
    Curr Opin Lipidol. 2020 Oct 6. doi: 10.1097/MOL.0000000000000713.
    PubMed     Abstract available
    
    
    
59. IBRAHIM S, Reeskamp LF, Stroes ESG, Watts GF, et al
    Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods.
    Curr Opin Lipidol. 2020 Oct 6. doi: 10.1097/MOL.0000000000000714.
    PubMed     Abstract available
    
    
    September 2020
60. WOLSKA A, Yang ZH, Remaley AT
    Hypertriglyceridemia: new approaches in management and treatment.
    Curr Opin Lipidol. 2020 Sep 29. doi: 10.1097/MOL.0000000000000710.
    PubMed     Abstract available
    
    
    June 2020
61. SORAN H, Cooper JA, Durrington PN, Capps N, et al
    Non-HDL or LDL cholesterol in heterozygous familial hypercholesterolaemia: findings of the Simon Broome Register.
    Curr Opin Lipidol. 2020 Jun 28. doi: 10.1097/MOL.0000000000000692.
    PubMed     Abstract available
    
    
    
62. BELANGER AM, Akioyamen L, Alothman L, Genest J, et al
    Evidence for improved survival with treatment of homozygous familial hypercholesterolemia.
    Curr Opin Lipidol. 2020 Jun 8. doi: 10.1097/MOL.0000000000000686.
    PubMed     Abstract available
    
    
    April 2020
63. BRANDTS J, Dharmayat KI, Ray KK, Vallejo-Vaz AJ, et al
    Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia?
    Curr Opin Lipidol. 2020 Apr 22. doi: 10.1097/MOL.0000000000000675.
    PubMed     Abstract available
    
    
    
64. BAJAJ A, Cuchel M
    Homozygous familial hypercholesterolemia: what treatments are on the horizon?
    Curr Opin Lipidol. 2020 Apr 22. doi: 10.1097/MOL.0000000000000677.
    PubMed     Abstract available
    
    
    January 2020
65. D'ERASMO L, Di Costanzo A, Arca M
    Autosomal recessive hypercholesterolemia: update for 2020.
    Curr Opin Lipidol. 2020 Jan 31. doi: 10.1097/MOL.0000000000000664.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge.